RAS inhibitors, beta blockers after discharge improve outcomes in MI with mid range EF - Video

Published On 2022-03-25T08:00:15+05:30 | Updated On 25 March 2022 9:54 AM IST

Overview

Beta-blocker therapy at discharge in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction (MI) was associated with lower 2-year rates of major adverse cardiac events (MACE). The Renin-angiotensin-system (RAS) inhibitor therapy at discharge after acute MI with heart failure with mildly reduced EF was associated with lower rates of rehospitalization due to heart failure. Furthermore, the Patients with mildly reduced LVEF after acute MI had better 2-year clinical outcomes if they were on beta blockers or RAS inhibitors at discharge.The findings suggest that beta blockers and RAS inhibitors can be considered in patients with mildly reduced LVEF after an acute MI in the era of early coronary reperfusion therapy and contemporary optimal medical therapies.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751